2 documents found, page 1 of 1
Patiromer for the management of hyperkalemia in heart failure with reduced ejec...
Butler, Javed; Anker, Stefan D.; Lund, Lars H; Coats, Andrew J. S.; Filippatos, Gerasimos; Siddiqi, Tariq Jamal; Friede, Tim; Fabien, VincentAims: To investigate the impact of patiromer on the serum potassium level and its ability to enable specified target doses of renin-angiotensin-aldosterone system inhibitor (RAASi) use in patients with heart failure and reduced ejection fraction (HFrEF). Methods and results: A total of 1642 patients with HFrEF and current or a history of RAASi-related hyperkalemia were screened and 1195 were enrolled in the run...
Patiromer for the management of hyperkalaemia in patients receiving renin–angio...
Butler, Javed; Anker, Stefan D.; Siddiqi, Tariq Jamal; Coats, Andrew J. S.; Dorigotti, Fabio; Filippatos, Gerasimos; Friede, Tim; Göhring, Udo‐MichaelAims: In patients with current or a history of hyperkalaemia, treatment with renin-angiotensin-aldosterone system inhibitors (RAASi) is often compromised. Patiromer, a novel potassium (K+ ) binder, may improve serum K+ levels and adherence to RAASi. Methods: The DIAMOND trial will enroll ∼820 patients with heart failure with reduced ejection fraction (HFrEF; ejection fraction ≤40%). Patients meeting the screeni...